Stroke prevention in AF

Atrial Fibrillation Anticoagulation in negligence claims.

Expert witness reports on whether anticoagulation for atrial fibrillation met accepted standards, and whether a failure to prescribe or monitor warfarin or a DOAC caused a preventable stroke.

Instruct a cardiology expert Call 0800 161 3395
  • CHA₂DS₂-VASc anticoagulation failure
  • Missed AF stroke clinical negligence
  • Warfarin & DOAC expert evidence
  • Bolam · Bolitho · Montgomery
what we cover

Stroke risk in atrial fibrillation and the legal questions it raises.

Atrial fibrillation increases stroke risk roughly fivefold, and anticoagulation with warfarin or a direct oral anticoagulant reduces that risk substantially. Our cardiologists assess whether stroke prevention met accepted standards, and whether a failure to prescribe or monitor anticoagulation caused a preventable thromboembolic event.

Most instructions arise where AF was undiagnosed, anticoagulation was withheld despite an elevated CHA₂DS₂-VASc score, or monitoring of warfarin or a DOAC fell below accepted standards. The decisions are tested against the current NICE and ESC atrial fibrillation guidance.

  • Breach questions address whether AF was identified, whether the CHA₂DS₂-VASc score was calculated, and whether anticoagulation was offered in line with current guidance.
  • Causation questions turn on whether timely anticoagulation would have prevented the stroke on the balance of probabilities, including material contribution where pre-existing vascular disease is present.
  • Bleeding risk assessment — the HAS-BLED score — must be documented and balanced against stroke risk. Reports examine whether contraindications were appropriately weighed.
  • Monitoring compliance for warfarin (INR control) and DOACs (renal function) is frequently in scope, particularly where subtherapeutic levels preceded the event.
Clinical scope

The clinical questions our cardiologists answer.

Reports address the cardiology decisions in issue against current guidance and the Bolam and Bolitho standard.

Included in scope

Questions addressed

  • Whether AF was identified on ECG or ambulatory monitoring, and whether opportunistic screening was offered in line with current guidance.
  • Whether the CHA₂DS₂-VASc score was calculated and whether anticoagulation was offered where indicated, including documentation of patient refusal.
  • Whether warfarin or DOAC choice and dosing complied with current practice, including renal function and drug interaction checks.
  • Whether INR monitoring for warfarin met the target range and whether subtherapeutic or supratherapeutic levels contributed to the event.
  • Whether, on the balance of probabilities, timely anticoagulation would have prevented the stroke or reduced its severity.
Out of scope

Not covered without separate instruction

  • Rate or rhythm control strategy for AF, including ablation and cardioversion, which sits with electrophysiology instruction.
  • Cardiac surgical decisions for AF, such as left atrial appendage occlusion, addressed via cardiac surgery instruction.
  • Examination of the claimant or prognosis evaluation, which requires a separate condition and prognosis report.
  • Quantum, life expectancy and care needs, addressed through dedicated reports where the case progresses to that stage.
Common cases

Common scenarios we report on.

These patterns recur in atrial fibrillation anticoagulation claims, most turning on primary care or emergency department decisions.

  • Primary care · Undiagnosed AF

    AF missed on routine ECG

    Patient presented with palpitations; the ECG showed AF but was misinterpreted as sinus rhythm, and no anticoagulation was offered. A stroke followed months later. The report addresses whether AF was identifiable, whether the CHA₂DS₂-VASc score warranted anticoagulation, and whether timely intervention would have prevented the event.

    Often paired with: Breach of Duty Causation

  • Primary care · Risk stratification

    CHA₂DS₂-VASc score not calculated

    Known AF with multiple stroke risk factors; the CHA₂DS₂-VASc score was not documented and anticoagulation was withheld on perceived bleeding risk. A stroke followed. The report examines whether stroke risk was appropriately quantified and whether anticoagulation was indicated under current guidance.

    Often paired with: Breach of Duty Causation

  • Primary care · Monitoring failure

    Warfarin INR subtherapeutic for an extended period

    Patient on warfarin for AF; INR consistently below the therapeutic range due to inadequate monitoring. A stroke followed. The report addresses whether INR control met accepted standards and whether subtherapeutic levels materially contributed to the event.

    Often paired with: Screening & Merits Breach of Duty

  • A&E · DOAC contraindication

    DOAC prescribed despite renal impairment

    Patient with AF and chronic kidney disease; a DOAC was prescribed without a renal function check. A stroke followed. The report tests whether renal function was appropriately assessed and whether DOAC dosing complied with current guidance.

    Often paired with: Causation Condition & Prognosis

Reports

Report types commissioned for this condition.

These cases typically progress from screening into full liability work, with causation often the central battleground.

Approaching a deadline?

Instruct an expert in atrial fibrillation anticoagulation.

Send a short note on the alleged failings with the records bundle. Quotation returned the same working day; fast-track available where the trial window or limitation deadline requires it.

Instruct a cardiology expert Call 0800 161 3395

GMC-registered consultants CPR Part 35 compliant reports LAA rates available